Latest News

Latest News

Healthcare Innovation Is Not Always About Something New

Healthcare Innovation Is Not Always About Something New

Healthcare innovation is often associated with something new. A new technology. A new platform. A new device. A new digital service. But healthcare organizations do not always need to add something new to improve care. Sometimes, they need to change something that is...

read more
Clinical Trials Roundup | 18 Sept 2026

Clinical Trials Roundup | 18 Sept 2026

Definium Therapeutics’ DT120 meets its primary endpoint in the Phase 3 Panorama study in generalised anxiety disorder, AstraZeneca’s camizestrant misses its primary endpoint in the Phase III SERENA-4 study in first-line breast cancer, Vera Therapeutics’ atacicept cuts...

read more
Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

Vera Therapeutics has put a two-year kidney function dataset behind its bid for IgAN full approval. On 15 September 2026, the company reported the final efficacy analysis of the Phase 3 ORIGIN 3 trial. The trial tested Trutakna (atacicept-vymj) in adults with primary...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Rethinking Commercial Strategy for Late Biopharma Entrants

Rethinking Commercial Strategy for Late Biopharma Entrants

Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...

read more
Python Blood Molecule Opens Door to New Obesity Treatments

Python Blood Molecule Opens Door to New Obesity Treatments

Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...

read more
Weekly News Roundup | 30 March 2026

Weekly News Roundup | 30 March 2026

Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...

read more
Clinical Trials Roundup | 27 March 2026

Clinical Trials Roundup | 27 March 2026

An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...

read more
New Report Highlights Why CGTs Still Struggle at Market Access

New Report Highlights Why CGTs Still Struggle at Market Access

Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...

read more
The Radical Longevity Science Frontier

The Radical Longevity Science Frontier

For decades, longevity has been a frontier of scientific exploration, pushing the boundaries of what we believe is possible for human health and lifespan. While incremental progress has been made in understanding the biology of aging, we are now on the cusp of a new...

read more
Key Thoughts from the on! PLUS TPL Review

Key Thoughts from the on! PLUS TPL Review

The evolving PMTA landscape for nicotine pouches The recent FDA authorisation of on! PLUS nicotine pouches is a significant moment in helping meet tobacco harm reduction (THR) goals. They are the first products to pass a new, faster FDA programme, signifying a...

read more
From Flower to Pharmacy: The Science Behind Manuka Honey

From Flower to Pharmacy: The Science Behind Manuka Honey

Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...

read more
Weekly News Roundup | 23 March 2026

Weekly News Roundup | 23 March 2026

Your essential life science news  23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...

read more
Rethinking Commercial Strategy for Late Biopharma Entrants

Rethinking Commercial Strategy for Late Biopharma Entrants

Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...

read more
Python Blood Molecule Opens Door to New Obesity Treatments

Python Blood Molecule Opens Door to New Obesity Treatments

Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...

read more
Weekly News Roundup | 30 March 2026

Weekly News Roundup | 30 March 2026

Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...

read more
Clinical Trials Roundup | 27 March 2026

Clinical Trials Roundup | 27 March 2026

An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...

read more
New Report Highlights Why CGTs Still Struggle at Market Access

New Report Highlights Why CGTs Still Struggle at Market Access

Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...

read more
The Radical Longevity Science Frontier

The Radical Longevity Science Frontier

For decades, longevity has been a frontier of scientific exploration, pushing the boundaries of what we believe is possible for human health and lifespan. While incremental progress has been made in understanding the biology of aging, we are now on the cusp of a new...

read more
Key Thoughts from the on! PLUS TPL Review

Key Thoughts from the on! PLUS TPL Review

The evolving PMTA landscape for nicotine pouches The recent FDA authorisation of on! PLUS nicotine pouches is a significant moment in helping meet tobacco harm reduction (THR) goals. They are the first products to pass a new, faster FDA programme, signifying a...

read more
From Flower to Pharmacy: The Science Behind Manuka Honey

From Flower to Pharmacy: The Science Behind Manuka Honey

Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...

read more
Weekly News Roundup | 23 March 2026

Weekly News Roundup | 23 March 2026

Your essential life science news  23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Clinical Trials Roundup

Clinical Trials Roundup

This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...

read more
Power Outages as a Clinical Risk Multiplier in Healthcare

Power Outages as a Clinical Risk Multiplier in Healthcare

Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...

read more
The Physician Gap That’s Slowing Life Sciences

The Physician Gap That’s Slowing Life Sciences

We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...

read more
Protecting R&D and Clinical Trial Data in the Age of AI

Protecting R&D and Clinical Trial Data in the Age of AI

Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...

read more
Medical Writers Become Strategic Partners

Medical Writers Become Strategic Partners

In regulated drug development, documentation shapes how a program is understood long before regulators ever see it. Protocols, investigator brochures, integrated summaries, and submission-ready modules establish the scientific and strategic narrative of a development...

read more
Weekly News Roundup | 16 March 2026

Weekly News Roundup | 16 March 2026

Your essential life science news digest: the past week's biggest stories in pharma, biotech and healthcare. 👇 This week's life science news was defined by regulatory uncertainty and clinical momentum. A landmark FDA leadership departure sent rare disease stocks...

read more
Reflections and Healing at the End of Life

Reflections and Healing at the End of Life

Words To Begin At age 81, the author has lived a "life of letters" (perhaps three million words) addressing a wide variety of subjects during multiple careers: Systems Engineering (PhD at UCLA in 1976), Military Science (21 years on active duty, in high-tech...

read more

Further News

Glass Slides to AI: Digital Pathology Can Transform Cancer Care in the NHS

Every year, millions of pathology slides are produced in the UK, most still examined manually under a microscope. This century-old process, though reliable, is no longer fit for purpose. Pathology departments face mounting workforce pressures, with 78% pathologists...

Kidney Care’s $2.5 Billion Timing Problem

Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...

Blood Supplies Set For Vital Boost as Donation Rules Are Updated

Long-running campaign removes unnecessary barrier for blood donors, a victory for both patients and the blood donation service* Patients receiving acupuncture from appropriately qualified practitioners will no longer have to wait four months before donating blood,...

In Vivo CAR-T Therapy: The Next Frontier in Cell Therapy Explained

In vivo CAR-T therapy has travelled from laboratory concept to clinical reality faster than almost any modality in recent memory. Conventional cell therapy collects a patient’s T cells, engineers them in a specialist facility and returns them weeks later. The in vivo...

Cutting Through the Noise: How AI/ML Can Guide Target Selection for Vaccines

Modern vaccine research has entered an era of colossal data abundance. Researchers can now examine complete pathogen genomes and proteomes, measure hundreds of thousands of antigen-specific antibody responses, characterize immune-cell states at single-cell resolution...

Beyond Weight Loss: What Emerging GLP-1 Research Reveals

For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...

GLP-1 Side Effects: What the Evidence Actually Says

An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...

Bridging Cosmetic Science & Clinical Research: When Beauty Becomes Therapeutic

The evolving landscape of cosmetic science is increasingly defined by its convergence with clinical research, challenging long-standing distinctions between aesthetic enhancement and therapeutic intervention. Historically, cosmetics have been confined to products...

Asia Is No Longer Pharma’s Factory. It Is Becoming the Source

Two deals announced within days of each other this month read, on their own, like routine deal flow news. South Korea’s Alteogen signed its seventh platform licensing agreement with a global pharmaceutical company. Fujifilm and Taiho Pharmaceutical agreed to build...

Catching Pediatric Strabismus: When It Is More Than a Glare Reaction

Monocular eye closure in bright sunlight glare can often be interpreted as a benign photic response in pediatric patients. However, the behavior may point to an early or intermittent manifestation of binocular vision dysfunction such as intermittent exotropia....

Regulation Is Pushing European Medtechs to Streamline Clinical Trials

Europe’s changing macroeconomic and regulatory environment is prompting the medtech industry to rethink clinical processes and technologies. New insights reveal focus on establishing a unified digital foundation as medtech companies look to optimise data strategy,...

Treating Antimicrobial Resistance as a Healthcare Infrastructure Priority

Modern healthcare depends on a basic assumption: when infections occur, clinicians will have medicines that can treat them. But antimicrobial resistance (AMR) is beginning to challenge that assumption at a systems level. For many years, AMR has been discussed...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.